Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (NASDAQ: QTRX) announced the participation of its CEO Masoud Toloue and CFO Vandana Sriram at the 45th Annual Goldman Sachs Global Healthcare Conference. The company specializes in ultrasensitive biomarker detection to advance scientific discovery. The fireside chat presentation is scheduled for June 12, 2024, at 2:40 p.m. EST and will be webcast live. Replays will be available for a time post-conference. For more details, visit the Investor Relations section on Quanterix's website.
Quanterix (NASDAQ: QTRX), a leader in biomarker detection technology, announced that its CEO, Masoud Toloue, will participate in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for May 29, 2024, at 11:40 a.m. ET and will be available via a live webcast.
Replays will be accessible for a time post-conference. For more details, visit Quanterix’s official website.
Quanterix , a biomarker detection company, reported financial results for Q1 2024 with revenue of $32.1 million, a 12.7% increase year-over-year. The company is focused on developing new assays to detect neuro-pathologies like Alzheimer's, Parkinson's, and Multiple Sclerosis. Key highlights include the launch of a blood test for Alzheimer's and maintaining a strong cash position. The company reaffirmed its 2024 financial guidance with revenue expected in the range of $139 to $144 million.
Quanterix (NASDAQ: QTRX) will host a conference call on May 8, 2024, to discuss its first quarter 2024 financial results. The press release will be issued on May 7, 2024, after the market closes. Interested investors can access the webcast and dial-in information on the Quanterix website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.